Ex vivo lung perfusion as a human platform for preclinical small molecule testing

Area of Science:

• Pulmonary Medicine
• Translational Research
• Pharmacology

Background:

• Acute Respiratory Distress Syndrome (ARDS) is a severe condition with high mortality and limited treatment options.
• Existing pharmacologic interventions for ARDS have largely failed, highlighting the need for effective human models to test new therapies.
• FBXO3 is a proinflammatory E3 ligase-associated protein implicated in lung injury, with small molecules like BC1215 showing potential for therapeutic intervention.

Purpose of the Study:

• To establish and validate a human ex vivo lung perfusion (EVLP) model for preclinical assessment of ARDS therapeutics.
• To investigate the efficacy of BC1215, an FBXO3 inhibitor, in mitigating endotoxemic lung injury within the EVLP model.
• To analyze the molecular mechanisms underlying BC1215's therapeutic effects on inflammatory pathways in human lungs.

Main Methods:

• Human lungs unsuitable for transplant were utilized in an ex vivo lung perfusion (EVLP) system for 6 hours.
• Endotoxemic injury was induced using lipopolysaccharide (LPS) infusion.
• BC1215 was administered post-LPS challenge to assess its therapeutic potential.
• Lung function (oxygenation) and inflammatory markers were measured.
• RNA sequencing and transcriptomic analysis were performed on lung biopsies to evaluate gene expression changes.

Main Results:

• LPS infusion induced significant inflammatory injury and impaired oxygenation in the EVLP model.
• BC1215 treatment effectively rescued oxygenation and reduced inflammatory cytokines in bronchoalveolar lavage fluid.
• Transcriptomic analysis revealed robust inflammatory gene induction by LPS, particularly NF-κB-associated transcripts.
• BC1215 significantly suppressed LPS-induced inflammatory and host defense gene expression and antagonized NF-κB activity.

Conclusions:

• Ex vivo lung perfusion (EVLP) serves as a viable human platform for preclinical evaluation of therapeutic agents for ARDS.
• BC1215 demonstrates significant therapeutic potential by suppressing inflammatory responses and NF-κB signaling in an LPS-induced lung injury model.
• This study validates the use of EVLP coupled with transcriptomic analysis to predictively assess the efficacy of novel chemical entities targeting pathways like FBXO3.